Int J Stem Cells.  2023 Feb;16(1):16-26. 10.15283/ijsc21189.

Establishing Rationale for the Clinical Development of Cell Therapy Products: Consensus between Risk and Benefit

• Han S
• Yim HW
• Jeong H
• Choi S
• Han S

• KMID: 2539617
• DOI: http://doi.org/10.15283/ijsc21189

Abstract

Despite long-term research achievements, the development of cell therapy (CT) products remains challenging. This is because the risks experienced by the subject and therapeutic effects in the clinical trial stage are unclear due to the various uncertainties of CT when administered to humans. Nevertheless, as autologous cell products for systemic administration have recently been approved for marketing, CT product development is accelerating, particularly in the field of unmet medical needs. The human experience of CT remains insufficient compared with other classes of pharmaceuticals, while there are countless products for clinical development. Therefore, for many sponsors, understanding the rationale of human application of an investigational product based on the consensus and improving the ability to apply it appropriately for CT are necessary. Thus, defining the level of evidence for safety and efficacy fundamentally required for initiating the clinical development and preparing it using a reliable method for CT. Furthermore, the expertise should be strengthened in the design of the first-in-human trial, such as the starting dose and dose-escalation plan, based on a sufficiently acceptable rationale. Cultivating development professionals with these skills will increase the opportunity for more candidates to enter the clinical development phase.

Keyword

Cell- and tissue-based therapy; Drug development; Drug approval; Stem cells

Figure

• 

  Fig. 1 Key questions and supporting evidence in preclinical drug develo-pment.

Reference

References

1. Picanco-Castro V, Gonçalves Pereira C, Swiech K, Ribeiro Malmegrim KC, Tadeu Covas D, Silveira Porto G. 2020; Emer-ging CAR T cell therapies: clinical landscape and patent technological routes. Hum Vaccin Immunother. 16:1424–1433. DOI: 10.1080/21645515.2019.1689744. PMID: 31702480. PMCID: PMC7482707.

2. Laurencin CT, McClinton A. 2020; Regenerative cell-based therapies: cutting edge, bleeding edge, and off the edge. Regen Eng Transl Med. 6:78–89. DOI: 10.1007/s40883-020-00147-1. PMID: 33344756. PMCID: PMC7748257.

3. Peng B, Ming Y, Yang C. 2018; Regulatory B cells: the cutting edge of immune tolerance in kidney transplantation. Cell Death Dis. 9:109. DOI: 10.1038/s41419-017-0152-y. PMID: 29371592. PMCID: PMC5833552.

4. Watanabe Y, Tsuchiya A, Terai S. 2021; The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future. Clin Mol Hepatol. 27:70–80. DOI: 10.3350/cmh.2020.0194. PMID: 33317249. PMCID: PMC7820202. PMID: a62cb92071244c0eb0decad045521525.

5. Moll G, Ankrum JA, Kamhieh-Milz J, Bieback K, Ringdén O, Volk HD, Geissler S, Reinke P. 2019; Intravascular mesenchymal stromal/stem cell therapy product diversification: time for new clinical guidelines. Trends Mol Med. 25:149–163. DOI: 10.1016/j.molmed.2018.12.006. PMID: 30711482.

6. Golchin A, Farahany TZ. 2019; Biological products: cellular therapy and FDA approved products. Stem Cell Rev Rep. 15:166–175. DOI: 10.1007/s12015-018-9866-1. PMID: 30623359.

7. Shukla V, Seoane-Vazquez E, Fawaz S, Brown L, Rodri-guez-Monguio R. 2019; The landscape of cellular and gene therapy products: authorization, discontinuations, and cost. Hum Gene Ther Clin Dev. 30:102–113. DOI: 10.1089/humc.2018.201. PMID: 30968714.

8. Xu J, Sim JW. 2018; Characteristics of corporate R&D investment in emerging markets: evidence from manufacturing industry in China and South Korea. Sustainability. 10:3002. DOI: 10.3390/su10093002.

9. Bas TG, Oliu Castillo C. 2016; Biosimilars in developed and developing East and Southeast Asian countries: Japan, South Korea, and Malaysia-overview, evolution, and regulations assessment. Biomed Res Int. 2016:5910403. DOI: 10.1155/2016/5910403. PMID: 27213153. PMCID: PMC4860213.

10. Mendicino M, Fan Y, Griffin D, Gunter KC, Nichols K. 2019; Current state of U.S. Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon. Cytotherapy. 21:699–724. DOI: 10.1016/j.jcyt.2019.04.002. PMID: 31196820.

11. Herberts CA, Kwa MS, Hermsen HP. 2011; Risk factors in the development of stem cell therapy. J Transl Med. 9:29. DOI: 10.1186/1479-5876-9-29. PMID: 21418664. PMCID: PMC3070641.

12. Izeta A, Herrera C, Mata R, Astori G, Giordano R, Herná-ndez C, Leyva L, Arias S, Oyonarte S, Carmona G, Cuende N. 2016; Cell-based product classification procedure: what can be done differently to improve decisions on borderline products? Cytotherapy. 18:809–815. DOI: 10.1016/j.jcyt.2016.03.292. PMID: 27209278.

13. Therapeutic Goods Administration, Department of Health, Australian Government. 2018. Intended use: interpretation of homologous use Australian Regulatory Guidelines for Biologicals (ARGB). Version 1.0. Commonwealth of Australia;Woden: DOI: 10.1016/j.jcyt.2016.03.292.

14. Schmidt C. 2011; FDA approves first cell therapy for wrinkle-free visage. Nat Biotechnol. 29:674–675. DOI: 10.1038/nbt0811-674. PMID: 21822225.

15. Dunkin BS, Lattermann C. 2013; New and emerging techniques in cartilage repair: MACI. Oper Tech Sports Med. 21:100–107. DOI: 10.1053/j.otsm.2013.03.003. PMID: 24072960. PMCID: PMC3780415.

16. Falanga V, Faria K, Bollenbach T. Lanza R, Langer R, Vacanti J, editors. 2014. Bioengineered skin constructs. Prin-ciples of Tissue Engineering. 4th ed. Academic Press;London: p. 1619–1643. DOI: 10.1016/B978-0-12-398358-9.00077-X.

17. Bach PB, Giralt SA, Saltz LB. 2017; FDA approval of tisagenlecleucel: promise and complexities of a $475 000 cancer drug. JAMA. 318:1861–1862. DOI: 10.1001/jama.2017.15218. PMID: 28975266.

18. Ali S, Kjeken R, Niederlaender C, Markey G, Saunders TS, Opsata M, Moltu K, Bremnes B, Grønevik E, Muusse M, Håkonsen GD, Skibeli V, Kalland ME, Wang I, Buajordet I, Urbaniak A, Johnston J, Rantell K, Kerwash E, Schuessler-Lenz M, Salmonson T, Bergh J, Gisselbrecht C, Tzogani K, Papadouli I, Pignatti F. 2020; The European Medi-cines Agency review of kymriah (Tisagenlecleucel) for the treatment of acute lymphoblastic leukemia and diffuse large B-Cell lymphoma. Oncologist. 25:e321–e327. DOI: 10.1634/theoncologist.2019-0233. PMID: 32043764. PMCID: PMC7011647.

19. Patel S, Burga RA, Powell AB, Chorvinsky EA, Hoq N, McCormack SE, Van Pelt SN, Hanley PJ, Cruz CRY. 2019; Beyond CAR T cells: other cell-based immunotherapeutic strategies against cancer. Front Oncol. 9:196. DOI: 10.3389/fonc.2019.00196. PMID: 31024832. PMCID: PMC6467966.

20. Upadhaya S, Yu JX, Shah M, Correa D, Partridge T, Campbell J. 2021; The clinical pipeline for cancer cell therapies. Nat Rev Drug Discov. 20:503–504. DOI: 10.1038/d41573-021-00100-z. PMID: 34088999.

21. Roselli E, Faramand R, Davila ML. 2021; Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes. J Clin Invest. 131:e142030. DOI: 10.1172/JCI142030. PMID: 33463538. PMCID: PMC7810492.

22. Jo Y, Ali LA, Shim JA, Lee BH, Hong C. 2020; Innovative CAR-T cell therapy for solid tumor; current duel between CAR-T spear and tumor shield. Cancers (Basel). 12:2087. DOI: 10.3390/cancers12082087. PMID: 32731404. PMCID: PMC7464778. PMID: 59525d6b4c6940c6ac376520b1b6f647.

23. Hou B, Tang Y, Li W, Zeng Q, Chang D. 2019; Efficiency of CAR-T therapy for treatment of solid tumor in clinical trials: a meta-analysis. Dis Markers. 2019:3425291. DOI: 10.1155/2019/3425291. PMID: 30886654. PMCID: PMC6388318.

24. Townsend MH, Bennion K, Robison RA, O'Neill KL. 2020; Paving the way towards universal treatment with allogenic T cells. Immunol Res. 68:63–70. DOI: 10.1007/s12026-020-09119-7. PMID: 32096010.

25. Alnaggar M, Xu Y, Li J, He J, Chen J, Li M, Wu Q, Lin L, Liang Y, Wang X, Li J, Hu Y, Chen Y, Xu K, Wu Y, Yin Z. 2019; Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma. J Immunother Cancer. 7:36. DOI: 10.1186/s40425-019-0501-8. PMID: 30736852. PMCID: PMC6368763.

26. Deinsberger J, Reisinger D, Weber B. 2020; Global trends in clinical trials involving pluripotent stem cells: a systematic multi-database analysis. NPJ Regen Med. 5:15. DOI: 10.1038/s41536-020-00100-4. PMID: 32983575. PMCID: PMC7486930.

27. Borlongan CV. 2019; Concise review: stem cell therapy for stroke patients: are we there yet? Stem Cells Transl Med. 8:983–988. DOI: 10.1002/sctm.19-0076. PMID: 31099181. PMCID: PMC6708064.

28. Kawabori M, Shichinohe H, Kuroda S, Houkin K. 2020; Clinical trials of stem cell therapy for cerebral ischemic stroke. Int J Mol Sci. 21:7380. DOI: 10.3390/ijms21197380. PMID: 33036265. PMCID: PMC7582939. PMID: e7c4c0945cc54cb59e75fd0f983ee549.

29. Lalu MM, Mazzarello S, Zlepnig J, Dong YYR, Montroy J, McIntyre L, Devereaux PJ, Stewart DJ, David Mazer C, Barron CC, McIsaac DI, Fergusson DA. 2018; Safety and efficacy of adult stem cell therapy for acute myocardial infarction and ischemic heart failure (SafeCell Heart): a systematic review and meta-analysis. Stem Cells Transl Med. 7:857–866. DOI: 10.1002/sctm.18-0120. PMID: 30255989. PMCID: PMC6265630.

30. Barker RA, Carpenter MK, Forbes S, Goldman SA, Jamieson C, Murry CE, Takahashi J, Weir G. 2018; The challenges of first-in-human stem cell clinical trials: what does this mean for ethics and institutional review boards? Stem Cell Reports. 10:1429–1431. DOI: 10.1016/j.stemcr.2018.04.010. PMID: 29742388. PMCID: PMC5995446.

31. Center for Biologics Evaluation and Research, US FDA. 2015. Considerations for the design of early-phase clinical trials of cellular and gene therapy products; guidance for industry. FDA;Silver Spring: DOI: 10.1007/s12026-020-09119-7.

32. Center for Biologics Evaluation and Research, US FDA. 2015. Guidance for FDA reviewers and sponsors: content and review of chemistry, manufacturing, and control (CMC) information for human somatic cell therapy investigational new drug applications (INDs). FDA;Rockville: DOI: 10.1007/s12026-020-09119-7.

33. Geigert J. Geigert J, editor. 2019. An effective CMC strategy is possible. The challenge of CMC regulatory compliance for biopharmaceuticals. Springer;Cham: p. 53–87. DOI: 10.1007/978-3-030-13754-0_3.

34. Andrade EL, Bento AF, Cavalli J, Oliveira SK, Schwanke RC, Siqueira JM, Freitas CS, Marcon R, Calixto JB. 2016; Non-clinical studies in the process of new drug development - Part II: good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies. Braz J Med Biol Res. 49:e5646. DOI: 10.1590/1414-431x20165646. PMID: 27982281. PMCID: PMC5188860.

35. Steinmetz KL, Spack EG. 2009; The basics of preclinical drug development for neurodegenerative disease indications. BMC Neurol. 9(Suppl 1):S2. DOI: 10.1186/1471-2377-9-S1-S2. PMID: 19534731. PMCID: PMC2697630.

36. Senderowicz AM. 2010; Information needed to conduct first-in-human oncology trials in the United States: a view from a former FDA medical reviewer. Clin Cancer Res. 16:1719–1725. DOI: 10.1158/1078-0432.CCR-09-2766. PMID: 20215544.

37. Mager DE, Woo S, Jusko WJ. 2009; Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab Pharmacokinet. 24:16–24. DOI: 10.2133/dmpk.24.16. PMID: 19252333. PMCID: PMC3727168.

38. Lee W, Cai Y, Lim TP, Teo J, Chua SC, Kwa AL. 2019; In vitro pharmacodynamics and PK/PD in animals. Adv Exp Med Biol. 1145:105–116. DOI: 10.1007/978-3-030-16373-0_8. PMID: 31364074.

39. Marx U, Akabane T, Andersson TB, Baker E, Beilmann M, Beken S, Brendler-Schwaab S, Cirit M, David R, Dehne EM, Durieux I, Ewart L, Fitzpatrick SC, Frey O, Fuchs F, Griffith LG, Hamilton GA, Hartung T, Hoeng J, Hogberg H, Hughes DJ, Ingber DE, Iskandar A, Kanamori T, Kojima H, Kuehnl J, Leist M, Li B, Loskill P, Mendrick DL, Neumann T, Pallocca G, Rusyn I, Smirnova L, Steger-Hartmann T, Tagle DA, Tonevitsky A, Tsyb S, Tra-pecar M, Van de Water B, Van den Eijnden-van Raaij J, Vulto P, Watanabe K, Wolf A, Zhou X, Roth A. 2020; Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development. ALTEX. 37:365–394. DOI: 10.14573/altex.2001241. PMID: 32113184. PMCID: PMC7863570.

40. Kopec AK, Yokokawa R, Khan N, Horii I, Finley JE, Bono CP, Donovan C, Roy J, Harney J, Burdick AD, Jessen B, Lu S, Collinge M, Sadeghian RB, Derzi M, Tomlinson L, Burkhardt JE. 2021; Microphysiological systems in early stage drug development: perspectives on current applications and future impact. J Toxicol Sci. 46:99–114. DOI: 10.2131/jts.46.99. PMID: 33642521.

41. 2009. Dec. ICH Guideline M3 (R2) on Non-clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals [Internet]. European Medicines Agency;London: Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-m3r2-non-clinical-safety-studies-conduct-human-clinical-trials-marketing-authorisation_en.pdf. cited 2019 Mar 24.

42. Settiagounder N. 2017; Histopathology evaluation and peer review for nonclinical studies: raw data compliance to GLP quality systems. J Regul Sci. 5:45–55.

43. Food and Drug Administration. 2021. Summary basis for regulatory action for idecabtagene vicleucel. FDA;Silver Spring:

44. European Medicines Agency. 2017. Assessment report for Alofisel. European Medicines Agency;London:

45. European Medicines Agency. 2018. Assessment report for Yes-carta. European Medicines Agency;London:

46. Food and Drug Administration. 2013. Draft Guidance for Industry: Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products; Availability. FDA;Rockville:

47. Food and Drug Administration. 2020. Chemistry, manufacturing, and control (CMC) information for human gene therapy investigational new drug applications (INDs). FDA;Rockville: